|
KMID : 0869620120290010048
|
|
Journal of Korean Society of Hospital Pharmacists
2012 Volume.29 No. 1 p.48 ~ p.55
|
|
|
Drug Use Evaluation of Arbekacin
|
|
Hwang Ji-Hee
Moon Mi-Kyoung
Kim Ju-Sin
Won Kyoung-Suk
Lee Chang-Seop
|
|
|
Abstract
|
|
|
Arbekacin is a semisynthetic aminoglycoside antibiotic. It is used for the treatment of
infections caused by multi-resistant bacteria including methicillin-resistant Staphylococcus
aureus (MRSA). It works by binding to the bacterial 30S ribosomal subunit, causing misreading of t-RNA which consequently, leaves the bacterium unable to synthesize proteins vital to its growth. Pharmacokinetic advantages such as concentration-dependant bactericidal activity and prolonged post-antibiotic effect are more appropriate than vancomycin. However, there are only a few reports of clinical data of this antibiotic use against MRSA infections. Therefore, this study was performed to evaluate the use of arbekacin and to evaluate the effects of arbekacin in the treatment of MRSA infections.
We retrospectively analyzed medical records of patients who received arbekacin in Chonbuk
National University Hospital from January 2009 to May 2010.
As result, 103 patients were studied, and the justification of use showed high rate of appropriate use(92.2%). Most of the critical(process) indicators also showed high rate of appropriate use(89.3%~100%). The incidence of complications in arbekacin use was nephrotoxicity 7.8% and hepatotoxicity 7.8%. In outcomes measure, the total therapeutic response rate showed 67%. This study showed that arbekacin was used appropriately. And arbekacin was not inferior drug to vancomycin(vancomycin therapeutic response rates: 66.9~88%) and it could be a good alternative drug for vancomycin in MRSA treatment.
|
|
|
KEYWORD
|
|
|
Arbekacin, Drug use evaluation, MRSA, Efficacy response
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|